International Journal of Bio-Pharma Research <p>International Journal of Bio-Pharma Research (ISSN: 2287-6898) is an International, Monthly, Open Access,&nbsp;<strong>UGC</strong>&nbsp;<strong>Approved [63681]</strong>&nbsp;journal.</p> <p>IJBPR publishing the finest peer reviewed research in the fields of Biological and Pharmaceutical Sciences on the basis of its novelty, originality, importance, interdisciplinary interest and accessibility. Our objective is to inform authors of the decision on their manuscript (s) within one week of submission after&nbsp;<strong>Rigorous Peer Review</strong>. Following acceptance, a paper will normally be published in the next issue.</p> <p><strong>HIGHLIGHTS</strong></p> <p>&nbsp; &nbsp;UGC Approve Journal&nbsp;<strong>[63681].</strong></p> <p>&nbsp; &nbsp;Rapid publication service with precise review process.</p> <p>&nbsp; &nbsp;Assignment of DOI&nbsp;number with CrossRef.</p> <p>&nbsp; &nbsp;Indexed in worldwide abstracting agencies.</p> <p><strong>Manuscript Submissions</strong>:<br>Authors can submit their manuscript/s prepared in MS Word including Tables and Figures (If Any) at appropriate positions. All communications should be addressed to&nbsp;<strong></strong></p> International Journal of Biopharma and Research en-US International Journal of Bio-Pharma Research 2287-6898 <p><strong style="box-sizing: border-box; color: rgba(0, 0, 0, 0.87); font-family: &amp;quot; noto sans&amp;quot;,-apple-system,blinkmacsystemfont,&amp;quot;segoe ui&amp;quot;,&amp;quot;roboto&amp;quot;,&amp;quot;oxygen-sans&amp;quot;,&amp;quot;ubuntu&amp;quot;,&amp;quot;cantarell&amp;quot;,&amp;quot;helvetica neue&amp;quot;,sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: bolder; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;">Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</strong></p> Effect of vagbhattokta tambula sevana as per ayurveda on mukha roga <p>The diseases of oral cavity termed as <em>Mukharoga </em>in Ayurveda which involve various pathological conditions such as; <em>Danta Gata Roga</em> and<em> Austha Gata Roga</em> etc. Ayurveda described that <em>Mukharogas</em> may occur at different site of oral cavity and <em>Acharya Charaka</em> has mentioned 64 <em>Mukha rogas</em> in <em>Swayathu Chikitsa Adhyaya</em> depended on <em>Doshik</em> predominance. <em>Vatika Mukha Roga, Paittik Mukha Roga, Kaphaja Mukha Roga</em> and <em>Sannipatika Mukha Roga</em> are some disease of oral cavity emphasized in Ayurveda classic. <em>Vagbhattokta Tambula Sevana</em> is an <em>Upkrama</em> of <em>Dinacharya</em> practices since long in India and it alter pathological manifestation of<em> Mukha rogas.</em> Considering this fact present article described effect of<em> Vagbhattokta Tambula Sevana</em> as an <em>Upkrama</em> of <em>Dinacharya.</em></p> Neha Rathore Smita Paul Ashutosh Kumar Jain ##submission.copyrightStatement## 2019-03-03 2019-03-03 8 3 2491 2493 10.21746/ijbpr.2019.8.3.1 Bioactive potential of Pseudomonas alcaliphila isolated from a marine sponge against human pathogens <p>Metabolite extraction is considered as one of the important steps in metabolomics, the marine metabolite are the new source of the most antimicrobial agents used in both pharmacological and biological applications. In the present study, sponge associated bacterial metabolites was investigated. A total of 20 bacterial strains were isolated from the sponge <em>Haliclona</em> sp., All the strains were screened primarily with cross streaking method against human bacterial pathogens. The potent isolate was chosen based on the good inhibitory activity and metabolite extraction was achieved using chloroform: methanol mixture. The metabolites were then checked for their antimicrobial activity by disk diffusion and also minimum inhibitory concentration was determined. Out of 20 bacterial strains, only one strain selected based on the good inhibitory activity against pathogens and the strain was identified as <em>Pseudomonas alcaliphila</em> based on the biochemical and16S rRNA sequencing. The results revealed that the metabolites exhibited high activity and it was found that <em>Klebsiella pneumoniae</em> was inhibited high with the diameter of 22 mm followed by <em>Salmonella </em>Typhi (15 mm), <em>E.coli</em> (12 mm), and <em>Bacillus subtilis</em> (15 mm). The MIC was observed at 31.25 µg/ml against all pathogens. Results of TLC exhibited the Rf value at 0.86 and the FTIR results revealed the presence of C=o, amide bond, amino acids and methoxy groups. In GC-MS results showed that the metabolites mostly contain fatty acids and alkenes compounds. Thus, this marine active compound was considered as a novel compound for biological applications and may be a potential drug for therapeutic use.</p> Sathiyamurthy K. Bavithra H. ##submission.copyrightStatement## 2019-03-03 2019-03-03 8 3 2494 2503 10.21746/ijbpr.2019.8.3.2 Performance of Solar cell fabricated using TiO2: rGO on glass and Si substrates prepared by Thermal Evaporation Technique <p>TiO<sub>2</sub>: rGO doped material is deposited on glass and Si substrates. These hetero nanostructures have multiple applications in photovoltaic because of their charge transport properties. In this study, we prepared tetragonal TiO<sub>2</sub>: rGO doped material is deposited on glass and Si substrates (NCs) using Thermal Evaporation method. The morphological properties of the NCs were investigated using X-ray diffraction, Field-emission scanning electron microscopy with EDAX analysis, Atomic force microscopy, and Photovoltaic studies analysis. The results showed that the surface area of the deposited films increased significantly and the anatase TiO<sub>2</sub>: rGO doped material is deposited on glass and Si substrates was efficient photovoltaic performance with the other nanocomposites or the bare individual nanoparticles. It may be attributed to the increased active surface area, the increased adsorption of the light and target surface atoms, as well as efficient electron–hole transformation.</p> Ayeshamariam A. Prabhavathi G. Anuradha N. Afroos Banu A. Punithavelan N. Mohamed Saleem A. Jayachandran M. ##submission.copyrightStatement## 2019-03-07 2019-03-07 8 3 2504 2513 10.21746/ijbpr.2019.8.3.3 Development and Ex vivo evaluation of Rasagiline Mesylate mucoadhesive microemulsion for intranasal delivery using Box-Behnken design <p>Rasagiline mesylate (RM), an irreversible, selective inhibitor of MAO-B enzyme, is used in the treatment of Parkinson’s disease as oral tablets. It has low oral bioavailability (36%) due to hepatic first pass metabolism. Oral route of administration is associated with nausea and vomiting. Hence present research work was aimed to develop intranasal RM- loaded mucoadhesive microemulsions for brain targeting via olfactory pathway. The microemulsions were developed using Box Behnken design and evaluated for globule size, PDI, Zeta potential, pH, viscosity and <em>ex vivo</em> permeation on excised porcine nasal mucosa. Based on drug solubility, Capmul MCM, Tween 20 and Transcutol P were selected as oil, surfactant and cosurfactant respectively. Microemulsions were prepared by water titration method. Pseudoternary phase diagrams were constructed and the levels of surfactants, oil were selected. The influence of independent variables such as oil, Smix and water on responses size, zeta potential and flux were studied with the help of polynomial equations, contour plots and 3D response surface plots generated by design expert software. Optimized microemulsion formulation (ME18) was composed of oil (Capmul MCM), Smix (Tween 20: Transcutol P; 1:1), water and drug in the ratio 5:42:65:5.The globule size, zeta potential and flux of the optimized microemulsion was 150 nm, -29.6 mV and 291.7 μg/cm<sup>2</sup>/h respectively. Mucoadhesive agent (Chitosan) was added at 0.5% concentration to optimized microemulsion formulation (MME18). The size, zeta potential and flux of the MME18 was 176.4 nm, 12.1 mV and 323.1 μg/cm<sup>2</sup>/h respectively. The flux of ME18 and MME 18 was significantly higher than drug solution. The enhancement ratio of MME 18 was 4.2 times to that of drug solution, indicating potential advantage of microemulsion formulation.</p> Krishnaveni Janapareddi Anilgoud Kandhula ##submission.copyrightStatement## 2019-03-01 2019-03-01 8 3 2514 2522 10.21746/aps.2018.8.3.4